Introduction: Fibrosing cholestatic hepatitis (FCH) is an aggressive form of hepatitis C which is seen following liver transplantation (OLT) and it carries high mortality rate. Factors associated with development of FCH are not well defined.
Materials and Methods: From Jan 2009 through July 2012, 218 adult patients underwent OLT and 77 (35%) had hepatitis C. 6 (7.8%) patients with recurrent HCV had biopsy proven FCH. Data were collected on donor and recipient characteristics. Immunosupression was protocol based and all but one received tacrolimus. We matched 4 controls per case who were transplanted for HCV over the same time period without FCH. Liver biopsies were performed every 6 -12 months. Analysis was performed using Fisher's exact test and logistic regression.
Results: The mean time to FCH was 20 weeks. Patients who received a gender mismatch organ were 12-fold more likely to develop FCH, OR=12.1 [95%CI 1.2-123], p=0.026. CMV negative patients who received a CMV positive organ were 7.6 times more likely to develop FCH OR=7.6 [95% CI 1.1 -54], p=0.04. After controlling for donor age and steroid treated rejection gender mismatch remained a significant predictor OR=10.6 [95% CI 0.99-118], p=0.05. 5 of the 6 FCH (83%) patients died compared to no deaths in controls. The characteristics of FCH vs. non-FCH groups are shown in the Table.
|FCH (n=6)||Non-FCH (n=24)||P Values|
|PreOLT Mean HCV viral load IU/ml||1,827,971||866,955||0.14|
|Genotype 1||6 (100%)||24 (100%)|
|Mean donor age (years-old)||41||34||0.16|
|Treated for rejection (%)||1 (16%)||5 (21%)||1|
|Gender mismatch||5 (83%)||7 (29%)||0.029|
|Donor CMV+/Recipient CMV-||4 (66%)||5 (21%)||0.049|
|CMV viremia post OLT||6 (100%)||6 (25%)||0.002|
|Gender & CMV mismatch||3 (50%)||0||0.005|
Conclusions: Gender and CMV mismatch were strong predictors of FCH in HCV recipients following OLT. Post-OLT CMV viremia was associated with FCH. If confirmed, donor gender and CMV status could influence donor selection for hepatitis C recipients and centers may adapt more aggressive prophylaxis against CMV.
To cite this abstract in AMA style:Yazici C, Jacobs C, Ahrens W, Zamor P, Schmeltzer P, Casingal V, Eskind L, Levi D, Hayes D, Russo M. Predictors of Fibrosing Cholestatic Hepatitis Development Following Liver Transplantation: Potential Impact on Donor Selection and CMV Prophylaxis [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/predictors-of-fibrosing-cholestatic-hepatitis-development-following-liver-transplantation-potential-impact-on-donor-selection-and-cmv-prophylaxis/. Accessed October 27, 2020.
« Back to 2013 American Transplant Congress